Merck & Co., Inc.

Merck & Co., Inc.

MRKNYSEHealthcare
$145.97
up +0.78 (+0.53%)

1-Year Price

+61.93% past year
Merck & Co., Inc. (MRK) 1-year price chart: up 61.93% from $90.13 on Oct 2025 to $145.95 on Oct 2026. Closing range $82.49 to $156.45.

EquityGlimpse Score

Overall
7.1/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
4

Valuation, profitability, financial health, dividend and sentiment scores for Merck & Co., Inc. (MRK) are available to EquityGlimpse members.

Market Cap
360.12B
P/E Ratio
14.42
EPS
$7.30
52W High
$156.92
52W Low
$82.01
Volume
11.1M
Beta
0.22
Dividend Yield
3.10%
Fair value estimate: sign up to see
Is MRK over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
4.06
Price to Book
5.01
EV/EBITDA
10.59
Free CF per Share
$4.94
Op. CF per Share
$6.58
Debt to Equity
0.96
Gross Margin
71.98%
Net Margin
28.12%

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

CEO
Robert Davis
Industry
Drug Manufacturers - General
Employees
74,000
IPO Date
1978-01-13
Country
US
Website
Unlock Full Analysis

Get the complete picture on Merck & Co., Inc.

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for MRK and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.